MFAP4 Promotes Scar Formation by Regulating Macrophage‐Myofibroblast Transformation Through Activation of the TGF ‐β/Smad3 Signalling Pathway
Experimental Dermatology · 2026-07 · 35 (7)
DOI: 10.1111/exd.70314 ↗At a glance
Journal article in Experimental Dermatology, published online on 2026-07-10. Written by Zhu Zhu and 8 co-authors. Institution: Department of Medical Aesthetics, Hunan Aerospace Hospital, Changsha, Hunan, China. Major MEDLINE topics: Smad3 Protein, Macrophages, Myofibroblasts, Transforming Growth Factor beta. 42 references. The full text is freely available in PubMed Central. Funded by: Natural Science Foundation of Hunan Province, Key Project of Hunan Administration of Traditional Chinese Medicine, Scientific Research Project of Hunan Health Commission.
Abstract (original language)
Hypertrophic scar is a pathological consequence of abnormal wound healing, marked by excessive fibroblast proliferation and extracellular matrix (ECM) accumulation. Macrophage‐to‐myofibroblast transformation (MMT) plays a key role in this process, but its regulatory mechanisms remain under investigation. This study found that microfibril‐associated protein 4 (MFAP4) is significantly upregulated in mice scar tissue and is closely associated with the MMT process. In a mouse excision injury model, knockdown of MFAP4 in vivo macrophages using adeno‐associated virus (AAV)‐mediated RNA interference significantly reduced dermal thickening and disorganized collagen fibre deposition in mice scar tissues. Macrophage infiltration, expression of the myofibroblast marker α‐SMA, and the proportion of MMT cells (F4/80 + α‐SMA + ) were shown to be remarkably reduced. In vitro, TGF‐β1 induces elevated MFAP4 expression within mouse‐derived bone marrow‐derived macrophages (BMDMs) and promotes MMT. MFAP4 knockdown inhibits TGF‐β1‐induced myofibroblast transformation and expression of ECM synthesis‐related molecules (α‐SMA, Col‐I and Vimentin), while MFAP4 overexpression enhances these effects. Mechanistic studies suggest that MFAP4 regulates this process via the TGF‐β/Smad3 signalling activation. MFAP4 promotes Smad3 phosphorylation (p‐Smad3), and overexpression of Smad3 in MFAP4‐knockdown mouse‐derived BMDMs reverses the inhibitory effects of MFAP4 deficiency on MMT and ECM synthesis. These results reveal a key role for the MFAP4‐TGF‐β/Smad3 axis in regulating MMT‐driven scar formation, providing novel insights into the mechanisms of hypertrophic scarring in mice and underlying therapeutic targets for clinical intervention.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medical Aesthetics, Hunan Aerospace Hospital, Changsha, Hunan, China.
- Department of Dermatology, The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha, Hunan, China.
Funding
- Natural Science Foundation of Hunan Province
- Key Project of Hunan Administration of Traditional Chinese Medicine
- Scientific Research Project of Hunan Health Commission
- Changsha Municipal Natural Science Foundation Project
- Key Project of Aerospace Medicine
- Hospital-level Project of Hunan Aerospace Hospital
Cite
APA
Zhu, Z., Dai, J., Li, J., Zhang, M., Liu, C., Hu, J., Jiang, C., Wang, J., & Peng, Y. (2026). MFAP4 Promotes Scar Formation by Regulating Macrophage‐Myofibroblast Transformation Through Activation of the TGF ‐β/Smad3 Signalling Pathway. Experimental Dermatology, 35(7). https://doi.org/10.1111/exd.70314
Vancouver
Zhu Z, Dai J, Li J, Zhang M, Liu C, Hu J, et al. MFAP4 Promotes Scar Formation by Regulating Macrophage‐Myofibroblast Transformation Through Activation of the TGF ‐β/Smad3 Signalling Pathway. Experimental Dermatology. 2026;35(7). doi:10.1111/exd.70314
BibTeX
@article{Zhu2026,
author = {Zhu, Zhu and Dai, Jing and Li, Jinglin and Zhang, Mengyao and Liu, Chao and Hu, Jiaxiong and Jiang, Chufeng and Wang, Jingpei and Peng, Youhua},
title = {MFAP4 Promotes Scar Formation by Regulating Macrophage‐Myofibroblast Transformation Through Activation of the TGF ‐β/Smad3 Signalling Pathway},
journal = {Experimental Dermatology},
year = {2026},
volume = {35},
number = {7},
doi = {10.1111/exd.70314}
}
EUVIMED